Arrivent BioPharma, Inc. (AVBP)
30.34
+0.60
(+2.02%)
USD |
NASDAQ |
Sep 22, 16:00
30.34
0.00 (0.00%)
After-Hours: 18:30
Arrivent BioPharma Total Liabilities (Quarterly) : 27.88M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 27.88M |
| March 31, 2026 | 25.32M |
| December 31, 2025 | 25.94M |
| September 30, 2025 | 21.56M |
| June 30, 2025 | 19.64M |
| March 31, 2025 | 12.95M |
| December 31, 2024 | 17.29M |
| September 30, 2024 | 15.22M |
| Date | Value |
|---|---|
| June 30, 2024 | 12.20M |
| March 31, 2024 | 10.12M |
| December 31, 2023 | 11.80M |
| September 30, 2023 | 10.10M |
| June 30, 2023 | 12.81M |
| March 31, 2023 | |
| December 31, 2022 | 8.371M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Cytokinetics, Inc. | 2.098B |
| Gilead Sciences, Inc. | 37.62B |
| Ionis Pharmaceuticals, Inc. | 2.555B |
| Vertex Pharmaceuticals, Inc. | 7.175B |
| ACADIA Pharmaceuticals, Inc. | 436.29M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 394.72M |
| Shareholders Equity (Quarterly) | 366.84M |
| Debt to Equity Ratio | 0.001 |
| Current Ratio | 14.16 |
| Net Debt Paydown Yield | 0.00% |